Patents by Inventor Andrew P. Degnan

Andrew P. Degnan has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Oxazolidinones as modulators of mGluR5
    Patent number: 8691821
    Abstract: The disclosure generally relates to compounds of formula I, including their salts, as well as compositions and methods of using the compounds. The compounds are ligands, agonists and partial agonists for the mGluR5 receptor and may be useful for the treatment of various disorders of the central nervous system.
    Type: Grant
    Filed: November 2, 2011
    Date of Patent: April 8, 2014
    Assignee: Bristol-Myers Squibb Company
    Inventors: Andrew P. Degnan, Hong Huang, Lawrence B. Snyder, Fukang Yang, Kevin W. Gillman, Michael F. Parker
  • NK-1 and serotonin transporter inhibitors
    Patent number: 8383821
    Abstract: The invention encompasses compounds of Formula I, including pharmaceutically acceptable salts, their pharmaceutical compositions, and their use in treating disorders associated with an excess or imbalance of tachykinins or serotonin or both.
    Type: Grant
    Filed: November 13, 2009
    Date of Patent: February 26, 2013
    Assignee: Bristol-Meyers Squibb Company
    Inventors: Andrew P. Degnan, Kevin W. Gillman, Derek J. Denhart, Jonathan L. Ditta, Ramkumar Rajamani, Ying Han, George O. Tora
  • Oxazolidinones as Modulators of MGLUR5
    Publication number: 20120283264
    Abstract: The disclosure generally relates to compounds of formula I, including their salts, as well as compositions and methods of using the compounds. The compounds are ligands, agonists and partial agonists for the mGluR5 receptor and may be useful for the treatment of various disorders of the central nervous system.
    Type: Application
    Filed: November 2, 2011
    Publication date: November 8, 2012
    Inventors: Andrew P. Degnan, Hong Huang, Lawrence B. Snyder, Fukang Yang, Kevin W. Gillman, Michael F. Parker
  • Substituted heterocyclic ethers and their use in CNS disorders
    Patent number: 8026257
    Abstract: The invention encompasses compounds of Formula I, including pharmaceutically acceptable salts, their pharmaceutical compositions, and their use in treating CNS disorders.
    Type: Grant
    Filed: July 1, 2008
    Date of Patent: September 27, 2011
    Assignee: Bristol-Myers Squibb Company
    Inventors: Andrew P. Degnan, George O. Tora, Derek J. Denhart, Vivekananda M. Vrudhula, John E. Macor, Joanne J. Bronson
  • Anti-migraine spirocycles
    Patent number: 7842808
    Abstract: The present invention relates to compounds of Formula (I) as antagonists of calcitonin gene-related peptide receptors (“CGRP-receptor”), pharmaceutical compositions comprising them, methods for identifying them, methods of treatment using them and their use in therapy for treatment of neurogenic vasodilation, neurogenic inflammation, migraine and other headaches, thermal injury, circulatory shock, flushing associated with menopause, airway inflammatory diseases, such as asthma and chronic obstructive pulmonary disease (COPD), and other conditions the treatment of which can be effected by the antagonism of CGRP-receptors.
    Type: Grant
    Filed: January 5, 2007
    Date of Patent: November 30, 2010
    Assignee: Bristol-Myers Squibb Company
    Inventors: Prasad V. Chaturvedula, Ling Chen, Rita Civiello, Andrew P. Degnan, Gene M. Dubowchik, Xiaojun Han, Xiang Jun J. Jiang, Guanglin Luo, John E. Macor, Graham S. Poindexter, George O. Tora
  • Therapeutic agents for the treatment of migraine
    Patent number: 7772244
    Abstract: The present invention relates to compounds of Formula (I) as antagonists of calcitonin gene-related peptide receptors (“CGRP-receptor”), pharmaceutical compositions comprising them, methods for identifying them, methods of treatment using them and their use in therapy for treatment of neurogenic vasodilation, neurogenic inflammation, migraine and other headaches, thermal injury, circulatory shock, flushing associated with menopause, airway inflammatory diseases, such as asthma and chronic obstructive pulmonary disease (COPD), and other conditions the treatment of which can be effected by the antagonism of CGRP-receptors.
    Type: Grant
    Filed: March 28, 2005
    Date of Patent: August 10, 2010
    Assignee: Bristol-Myers Squibb Company
    Inventors: Andrew P. Degnan, Xiaojun Han, Gene M. Dubowchik, John E. Macor, Stephen E. Mercer
  • NK-1 and Serotonin Transporter Inhibitors
    Publication number: 20100087434
    Abstract: The invention encompasses compounds of Formula I, including pharmaceutically acceptable salts, their pharmaceutical compositions, and their use in treating disorders associated with an excess or imbalance of tachykinins or serotonin or both.
    Type: Application
    Filed: November 13, 2009
    Publication date: April 8, 2010
    Inventors: Andrew P. Degnan, Kevin W. Gillman, Derek J. Denhart, Jonathan L. Ditta, Ramkumar Rajamani, Ying Han, George O. Tora
  • Substituted heterocyclic ethers and their use in CNS disorders
    Patent number: 7632861
    Abstract: The invention encompasses compounds of Formula I, including pharmaceutically acceptable salts, their pharmaceutical compositions, and their use in treating CNS disorders.
    Type: Grant
    Filed: November 7, 2008
    Date of Patent: December 15, 2009
    Assignee: Bristol-Myers Squibb Company
    Inventors: Joanne J. Bronson, Andrew P. Degnan, William D. Schmitz
  • Heterocyclic anti-migraine agents
    Patent number: 7569578
    Abstract: The present invention relates to compounds of Formula (I) as antagonists of calcitonin gene-related peptide receptors (“CGRP-receptor”), pharmaceutical compositions comprising them, methods for identifying them, methods of treatment using them and their use in therapy for treatment of neurogenic vasodilation, neurogenic inflammation, migraine and other headaches, thermal injury, circulatory shock, flushing associated with menopause, airway inflammatory diseases, such as asthma and chronic obstructive pulmonary disease (COPD), and other conditions the treatment of which can be effected by the antagonism of CGRP-receptors.
    Type: Grant
    Filed: December 3, 2004
    Date of Patent: August 4, 2009
    Assignee: Bristol-Meyers Squibb Company
    Inventors: Guanglin Luo, Ling Chen, Andrew P. Degnan, Gene M. Dubowchik, John E. Macor, George O. Tora, Prasad V. Chaturvedula
  • Substituted Heterocyclic Ethers and Their Use in CNS Disorders
    Publication number: 20090124613
    Abstract: The invention encompasses compounds of Formula I, including pharmaceutically acceptable salts, their pharmaceutical compositions, and their use in treating CNS disorders.
    Type: Application
    Filed: November 7, 2008
    Publication date: May 14, 2009
    Inventors: Joanne J. Bronson, Andrew P. Degnan, William D. Schmitz
  • Substituted Heterocyclic Ethers and Their Use in CNS Disorders
    Publication number: 20090018132
    Abstract: The invention encompasses compounds of Formula I, including pharmaceutically acceptable salts, their pharmaceutical compositions, and their use in treating CNS disorders.
    Type: Application
    Filed: July 1, 2008
    Publication date: January 15, 2009
    Inventors: Andrew P. Degnan, George O. Tora, Derek J. Denhart, Vivekananda M. Vrudhula, John E. Macor, Joanne J. Bronson
  • Substituted Heterocyclic Ethers and Their Use in CNS Disorders
    Publication number: 20090018163
    Abstract: The invention encompasses compounds of Formula I, including pharmaceutically acceptable salts, their pharmaceutical compositions, and their use in treating CNS disorders.
    Type: Application
    Filed: July 9, 2008
    Publication date: January 15, 2009
    Inventors: William D. Schmitz, Irene E. Whitney, Andrew P. Degnan, Joanne J. Bronson
  • Anti-migraine treatments
    Patent number: 7314883
    Abstract: The present invention relates to methods of treating neurogenic vasodilation, neurogenic inflammaton, migraine and other headaches, thermal injury, circulatory shock, flushing associated with menopause, airway inflammatory diseases, such as asthma and chronic obstructive pulmonary disease (COPD), and other conditions the treatment of which can be effected by the antagonism of CGRP-receptors using pharmaceutical compositions comprising compounds of Formula (I)
    Type: Grant
    Filed: January 5, 2007
    Date of Patent: January 1, 2008
    Assignee: Bristol-Myers Squibb Company
    Inventors: Ling Chen, Prasad V. Chaturvedula, Rita Civiello, Andrew P. Degnan, Gene M. Dubowchik, Xiaojun Han, Xiang Jun J. Jiang, George N. Karageorge, Guanglin Luo, John E. Macor, Graham S. Poindexter, George O. Tora
  • Calcitonin gene related peptide receptor antagonists
    Patent number: 7220862
    Abstract: The present invention relates to compounds of Formula (I) as antagonists of calcitonin gene-related peptide receptors (“CGRP-receptor”), pharmaceutical compositions comprising them, methods for identifying them, methods of treatment using them and their use in therapy for treatment of neurogenic vasodilation, neurogenic inflammation, migraine and other headaches, thermal injury, circulatory shock, flushing associated with menopause, airway inflammatory diseases, such as asthma and chronic obstructive pulmonary disease (COPD), and other conditions the treatment of which can be effected by the antagonism of CGRP-receptors.
    Type: Grant
    Filed: December 5, 2003
    Date of Patent: May 22, 2007
    Assignee: Bristol-Myers Squibb Company
    Inventors: Prasad V. Chaturvedula, Ling Chen, Rita Civiello, Andrew P. Degnan, Gene M. Dubowchik, Xiaojun Han, Xiang Jun J. Jiang, George N. Karageorge, Guanglin Luo, John E. Macor, Graham Poindexter, George Tora
  • Aryloxyalkylamine NK-1/SSRI inhibitors
    Patent number: 7179926
    Abstract: The invention encompasses compounds of Formula I, including pharmaceutically acceptable salts and solvates, their pharmaceutical compositions, and their use in treating disorders associated with an excess or imbalance of tachykinins or serotonin or both.
    Type: Grant
    Filed: July 25, 2005
    Date of Patent: February 20, 2007
    Assignee: Bristol-Myers Squibb Company
    Inventors: Yazhong Huang, Shuanghua Hu, Andrew P. Degnan
  • Calcitonin gene related peptide receptor antagonists
    Publication number: 20040204397
    Abstract: The present invention relates to compounds of Formula (I) 1
    Type: Application
    Filed: December 5, 2003
    Publication date: October 14, 2004
    Inventors: Prasad V. Chaturvedula, Ling Chen, Rita Civiello, Charles Mark Conway, Andrew P. Degnan, Gene M. Dubowchik, Xiaojun Han, Xiang Jun J. Jiang, George N. Karageorge, Guanglin Luo, John E. Macor, Graham Poindexter, George Tora, Shikha Vig
  • Calcitonin gene related peptide receptor antagonists
    Publication number: 20040063735
    Abstract: The present invention relates to compounds of Formula (I) 1
    Type: Application
    Filed: May 27, 2003
    Publication date: April 1, 2004
    Inventors: Prasad V. Chaturvedula, Ling Chen, Rita Civiello, Charles Mark Conway, Andrew P. Degnan, Gene M. Dubowchik, Xiaojun Han, George N. Karageorge, Guanglin Luo, John E. Macor, Graham Poindexter, Shikha Vig